MicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure

Huatao Zhou; Weijie Tang; Jinfu Yang; Jinfu Yang; Jun Peng; Jianjun Guo; Chengming Fan; Chengming Fan; Chengming Fan

doi:10.3389/fcvm.2021.773083

Frontiers in Cardiovascular Medicine (Nov 2021)

MicroRNA-Related Strategies to Improve Cardiac Function in Heart Failure

Huatao Zhou,
Weijie Tang,
Jinfu Yang,
Jinfu Yang,
Jun Peng,
Jianjun Guo,
Chengming Fan,
Chengming Fan,
Chengming Fan

Affiliations

Huatao Zhou: Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
Weijie Tang: Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
Jinfu Yang: Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
Jinfu Yang: Department of Pharmacology, Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
Jun Peng: Department of Pharmacology, Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
Jianjun Guo: Hunan Fangsheng Pharmaceutical Co., Ltd. Changsha, China
Chengming Fan: Department of Cardiovascular Surgery, The Second Xiangya Hospital, Central South University, Changsha, China
Chengming Fan: Department of Pharmacology, Hunan Provincial Key Laboratory of Cardiovascular Research, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China
Chengming Fan: Hunan Fangsheng Pharmaceutical Co., Ltd. Changsha, China

DOI: https://doi.org/10.3389/fcvm.2021.773083
Journal volume & issue: Vol. 8

Abstract

Read online

Heart failure (HF) describes a group of manifestations caused by the failure of heart function as a pump that supports blood flow through the body. MicroRNAs (miRNAs), as one type of non-coding RNA molecule, have crucial roles in the etiology of HF. Accordingly, miRNAs related to HF may represent potential novel therapeutic targets. In this review, we first discuss the different roles of miRNAs in the development and diseases of the heart. We then outline commonly used miRNA chemical modifications and delivery systems. Further, we summarize the opportunities and challenges for HF-related miRNA therapeutics targets, and discuss the first clinical trial of an antisense drug (CDR132L) in patients with HF. Finally, we outline current and future challenges and potential new directions for miRNA-based therapeutics for HF.

Published in Frontiers in Cardiovascular Medicine

ISSN: 2297-055X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Diseases of the circulatory (Cardiovascular) system
Website: https://www.frontiersin.org/journals/cardiovascular-medicine

About the journal

Abstract

Keywords